Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells

Bone Marrow Transplantation

Volumn 28, Issue 6, 2001, Pages 563-571

  Yeoh, E J A ^a,b   Cunningham, J M ^a,c   Yee, G C ^d   Hunt, D ^a   Houston, J A ^a   Richardson, S L ^a   Stewart, C F ^a   Houghton, P J ^a   Bowman, L C ^a,c   Gajjar, A J ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Children; Filgram; High dose chemotherapy; Medulloblastoma; Peripheral blood stem cell; Topotecan

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

APHERESIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURGERY; CELL MOTILITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOXICITY; FEMALE; HIGH RISK PATIENT; HUMAN; IRRADIATION; MALE; MEDULLOBLASTOMA; METASTASIS; NERVE FIBER; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COSTS AND COST ANALYSIS; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TOPOTECAN;

EID: 0034780501     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703202     Document Type: Article

References (45)

1. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
2. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
3. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
4. Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
5. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
6. A review of autologous hematopoietic cell transplantation
7. Introduction: Current issues in high-dose chemotherapy and stem cell support
8. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
9. The biology and clinical uses of blood stem cells
10. The utilization of cytokines in stem cell mobilization strategies
11. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and recovery following high-dose chemotherapy
12. + cell collections are not necessarily cost-effective
13. Optimum methods to mobilize stem cells
14. Economic analyses of new technologies: The case of stem-cell transplantation
15. Clinical use of topoisomerase I inhibitors in anticancer treatment
16. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
17. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
18. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
19. The potential role of topotecan in the treatment of advanced breast cancer
20. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal collaborative study
21. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
22. Defining a therapeutic dose of peripheral blood stem cells
23. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
24. A program package for simulation and parameter estimation in pharmacokinetic systems
25. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy
26. Random-effects models for longitudinal data
27. Statistical aspects of the analysis of data from retrospective studies of disease
28. Nonparametric estimation from incomplete observations
29. Individual comparisons by ranking methods
30. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study
31. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
32. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
33. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
34. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
35. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
36. 2 in patients with advanced cancer
37. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease
38. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients
39. 2 of CY
40. Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients
41. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
42. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor
43. The relationships between the incidence of tumor contamination and number of phereses for stage IV breast cancer